PMID: 11932905Apr 5, 2002Paper

Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia

Cancer
Susan O'BrienH Kantarjian

Abstract

Homoharringtonine (HHT) has antileukemic activity in patients with Philadelphia chromosome (Ph) positive chronic myelogenous leukemia (CML). Combinations of HHT, interferon-alpha (IFN-alpha), and cytarabine (ara-C) have been studied in various CML phases. The objectives of this study were to evaluate the efficacy and toxicity profiles of a combination regimen of simultaneous HHT and IFN-alpha therapy in patients with chronic-phase CML who were not exposed previously to either agent. Forty-seven patients were treated: 37 patients with early chronic-phase CML (2 patients with clonal evolution) and 10 patients with late chronic-phase CML. Their median age was 62 years (range, 23-73 years). HHT was given at a dose of 2.5 mg/m(2) by continuous intravenous infusion over 24 hours daily for 5 days every month, and IFN-alpha was given daily at a target dose of 5 x 10(6) units/m(2) subcutaneously. Response, survival, and treatment toxicity were analyzed. Overall, the complete hematologic response (CHR) rate was 85%; the cytogenetic response rate was 66%, with major cytogenetic responses (Ph positive in < 35% of metaphases) in 49% of patients and complete cytogenetic responses in 21% of patients. The CHR rate, cytogenetic response rate, a...Continue Reading

References

Jun 25, 1988·British Medical Journal·L G Cohen, J P Rovers
May 1, 1985·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R P WarrellT S Gee
Mar 24, 1994·The New England Journal of Medicine·UNKNOWN Italian Cooperative Study Group on Chronic Myeloid LeukemiaMauro Fiacchini
Apr 2, 1998·Hematology/oncology Clinics of North America·H M KantarjianM Talpaz
Jul 31, 1999·Annals of Internal Medicine·S FaderlH M Kantarjian
Aug 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H M KantarjianM Talpaz
Oct 14, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H M KantarjianS O'Brien
Apr 5, 2001·The New England Journal of Medicine·B J DrukerC L Sawyers

❮ Previous
Next ❯

Citations

Oct 4, 2002·Hematological Oncology
Aug 2, 2008·Cancer Chemotherapy and Pharmacology·Richard M StoneUNKNOWN Cancer and Leukemia Group B
Oct 10, 2006·Chemical Communications : Chem Comm·Rachael A AncliffAdam J Sanderson
Sep 30, 2006·Cancer Immunology, Immunotherapy : CII·Jinfei ChenMichael Schmitt
Aug 11, 2010·Investigational New Drugs·Biren SaraiyaElizabeth A Poplin
Jul 7, 2007·Leukemia & Lymphoma·Yin-Jun LouJie Jin
Sep 16, 2011·Expert Opinion on Pharmacotherapy·Theo Daniel KimPhilipp le Coutre
Jul 24, 2013·Expert Opinion on Pharmacotherapy·Aziz NazhaAlfonso Quintás-Cardama
Apr 2, 2008·Expert Opinion on Pharmacotherapy·Alfonso Quintás-Cardama, Jorge Cortes
Aug 13, 2008·Expert Opinion on Investigational Drugs·Scott MillerPatrick J Mansky
Dec 29, 2004·Hematology·Chang Ying LuoYao Ping Wang
Oct 11, 2014·Expert Opinion on Pharmacotherapy·Omar Al UstwaniMeir Wetzler
May 26, 2016·Investigational New Drugs·Cynthia M NijenhuisJan H M Schellens
Jul 2, 2016·Expert Opinion on Drug Safety·Moussab DamlajSarit E Assouline
Jul 25, 2003·Cancer·Guillermo Garcia-ManeroHagop M Kantarjian
Feb 1, 2014·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Clement Chung
Sep 10, 2009·Cancer·Alfonso Quintás-CardamaJorge Cortes
Apr 3, 2003·British Journal of Cancer·S C PatersonH G Jørgensen
Jan 7, 2020·Journal of Materials Chemistry. B, Materials for Biology and Medicine·Zhanxia ZhangLijun Jia
Jun 1, 2018·Oncology and Therapy·Eric S Winer, Daniel J DeAngelo
Nov 25, 2003·Hematology·Junia V MeloJane F Apperley
Jul 24, 2004·Hematology/oncology Clinics of North America·Francis J GilesSusan M O'Brien
Dec 5, 2009·Best Practice & Research. Clinical Haematology·Elias JabbourHagop Kantarjian

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.